Peptide Therapeutics Market Size, Share, and Trends 2024 to 2033

The global peptide therapeutics market size was valued at USD 45.67 billion in 2023 and is expected to surpass around USD 80.44 billion by 2033 with a noteworthy CAGR of 5.63% from 2024 to 2033. The peptide therapeutics market growth is driven by an increasing prevalence of cancer and other metabolic diseases.

Key Takeaways

• North America dominated the market with the highest market share of 45.98% in 2023.
• Asia Pacific is projected to expand at the fastest CAGR of 6.86% between 2024 and 2033.
• By application, the metabolic disorder segment has captured around 22.90% of the market share in 2023.
• By application, the gastrointestinal disorder segment is poised to grow at a CAGR of 6.98% between 2024 and 2033.
• By type, the innovative segment has accounted for more than 60% of revenue share in 2023.
• By type, the generic segment is expected to expand at a notable CAGR of 5.41% between 2024 and 2033.
• By route of administration, the parenteral segment has generated more than 76% of revenue share in 2023.
• By route of administration, the oral segment is expanding at a CAGR of 6.68% between 2024 and 2033.
• By distribution channel, the hospital pharmacies segment has contributed around 39.95% of the market share in 2023.
• By distribution channel, the online drug stores segment is projected to grow at a CAGR of 6.15% between 2024 and 2033.
• By synthesis technology, the liquid phase peptide synthesis (LPPS) segment has recorded the largest market share of 45.96% in 2023.

Peptide Therapeutics Market in the US 2024 to 2033

The US peptide therapeutics market size was estimated at USD 18.47 billion in 2023 and is anticipated to reach around USD 32.24 billion by 2033. with a CAGR of 5.53% from 2024 to 2033.

Geographically, North America led the global peptide therapeutics market and captured more than 46% of the revenue share in 2023. The market's growth in North America is attributed to the rising demand for peptide drug products to treat cancer in the region. 

The development of the biotechnology and pharmaceutical industries has fueled market growth in North America. Europe shows potential market growth for peptides in the region. The well-established healthcare industry in Europe is considered a significant factor in the development of the market. However, high-priced peptide drugs in Europe hamper the growth of the market. 

Asia Pacific is anticipated to witness significant growth during 2023-2032. The rising prevalence of diabetes and infectious diseases is a driving factor for developing the market in the Asia Pacific. Developing the healthcare and biotech sectors in India and China is considered to fuel the demand for peptide drugs in the upcoming years. The growth of the peptide therapeutics market in the Asia Pacific is driven because of the availability of low-cost raw materials in the region. 

The rising development of novel peptide drugs for treating respiratory disorders and increasing investments in R&D activities propel the growth of the peptide therapeutics market in Latin America. Brazil is expected to dominate the peptide therapeutics market owing to the country's increased number of peptide therapies. Moreover, rapid adoption and increased awareness of peptide therapies in the Middle East and Africa will boost the demand for peptide therapeutics in these regions during the forecast period.

Peptide Therapeutics Market Overview

Naturally occurring peptides are strings of amino acids present in all living organisms. Peptide therapeutics are used for the treatment of various diseases. Peptides act as anti-infective growth hormones and even serve as ion channel ligands. Peptide therapeutics are capable of performing the same functions. 

The development in biotech and pharmaceutical industries worldwide has proven that peptide therapeutics can stimulate essential hormones. With growing age, peptide production in the human body is disrupted. Peptide therapeutics safely and effectively reintroduce vital peptides into the body. 

Peptide therapeutics treat neurological issues, diabetes, cancer, heart issues, and numerous other diseases. Moreover, peptide therapeutics offer muscle endurance, pain relief, injury recovery, and help in weight loss. Peptides are directly delivered into the bloodstream during the therapy. Peptide therapeutics have advanced rapidly in the pharmaceutical and biotech industries. Peptide therapeutics have gained popularity in the global nutrition industry in recent years. 

Furthermore, the healthcare sector across the globe has adopted the peptide drug delivery option rapidly. Peptide therapeutics have positively impacted human health by improving stamina and immunity and reducing undesired side effects caused by prolonged chronic diseases. 

Peptide Therapeutics Market Scope

Peptide Therapeutics Market Dynamics

The increased deployment of peptide molecules in the development of COVID-19 vaccines has already surged the growth of the global peptide therapeutics market. The market is showing potential growth and is predicted to maintain the same during the forecast period. Increasing cases of cancer and other metabolic disorders have boosted the demand for novel peptide conjugates. 

The increased demand for peptide conjugates in treating various conditions has forced vital players into strategic partnerships, collaboration, and agreements with other companies to expand their business portfolios.

The significant growth of the global peptide therapeutics market is driven by increased research and development (R&D) activities and investments in the market. Researchers focus on discovering peptide drugs to deal with diabetes and infectious disorders. The global peptide therapeutics market is predicted to witness noticeable growth in upcoming years owing to the increased clinical trials of targeted diseases. 

The increasing geriatric population is a major driving factor for developing the peptide therapeutics market. Moreover, technological advancements in the pharmaceutical industry are considered to drive the market's growth during the forecast period of 2024-2033. Several peptide conjugates help reduce inflammation, act as antioxidants and promote weight loss. A surge in the health & nutrition industry has boosted the demand for peptide drugs. 

However, the high cost associated with peptide drug discovery and development is likely to hamper the growth of the global peptide therapeutics market. Stringent regulations imposed by several governments for the development and manufacturing of peptide drugs are seen as a major restraining factor for the growth of the peptide therapeutics market. Furthermore, the risk of side effects caused by the longtime consumption of peptide drugs creates an obstacle to market growth. 

Covid-19 Impacts:

The World Health Organization (WHO) declared the spread of coronavirus as a global pandemic. The rapid spread of coronavirus led to a worldwide lockdown in 2020. The Covid-19 pandemic showed moderately positive impacts on the global peptide therapeutics market. In the initial phase of the pandemic, delayed clinical trials, approvals for peptide drugs, and lack of workforce impacted negatively and caused substantial economic loss for key players involved in the global peptide therapeutics market. Peptide drugs are considered a potential treatment for cancer and other metabolic disorders. The imposed restrictions during the pandemic resulted in a shortage of such drugs.

However, the increased number of peptide drug clinical trials for the treatment of Covid infection helped the market combat the loss. Researchers started developing novel peptide drugs for the treatment of Covid, this boosted investments in the market and fueled the growth of the global peptide therapeutics market. As of May 2020, researchers successfully developed 15 synthetic peptide drugs to treat acute respiratory distress syndrome (ARDS), which subsequently helped the healthcare sector deal with reactions caused by Covid-19 infection. 

Collectively more than 21 peptide drugs were used in the Covid-19 treatment. Along with this, peptide molecules were used to develop the covid vaccine. Considering the increased demand for peptides in the market, several governments supported the discovery and development of peptide drug conjugates. During this period, the U.S. Food & Drug Administration boosted the speed of approvals for peptide drugs in the market. Thus, increased deployment of peptide drugs and molecules in the Covid treatment resulted in increased revenue for critical players in the global peptide therapeutics market. 

Application Insights

The global peptide therapeutics market is segmented into gastrointestinal disorders, metabolic disorders, neurological disorders, cancer & others. A metabolic disorder is a dominating segment in the global peptide therapeutics market. The rising prevalence of metabolic conditions such as diabetes and heart disease has fueled the segment's growth. The growing geriatric population globally is considered a major driving factor for the development of the metabolic disorder segment. 

The cancer segment is the second-largest and fastest-growing global peptide therapeutics market. Peptides are considered a potential cytotoxic agent that can offer effective cancer treatment. Increased demand for quick yet effective remedies by the oncology sector has surged the growth of the cancer segment in recent years. Increasing discoveries for parenteral peptide drugs for cancer treatment is another driving factor for developing a segment in the global peptide therapeutics market. 

Type Insights

The global peptide therapeutics market is segmented into generic & innovative. The innovative segment dominates the global peptide therapeutics market and captured 60.20% of the revenue share in 2023. The increased investments in research and development (R&D) activities to discover novel peptide conjugates drive the growth of the innovative segment. Increasing prescriptions for peptide drugs to treat various disorders boosts the demand for innovative peptides. 

Rising healthcare expenses and high costs associated with peptide therapies are considered to grow the generic segment during the forecast period. The rising focus of several governments on the production and adoption of generic peptide drugs will fuel the growth of the generic segment. 

Route of Administration Insights

The global peptide therapeutics market is segmented into oral, parenteral, pulmonary, mucosal & others. The parenteral segments dominated the market in 2023 with a revenue share of around 76.02%. Most peptide drugs are delivered by injection, due to which the parenteral route of administration segment dominates the global peptide therapeutics market. 

The parenteral route of administration allows faster, more effective, and easy absorption of drugs. Researchers are focused on discovering novel peptide drugs that can be administered parenterally. On the other hand, oral and pulmonary segments in the route of administration are expected to witness significant growth during the forecast period. 

The development of the oral segment is driven by higher patient acceptability for oral drugs. However, the risk of inflammation caused by the pulmonary route of administration is likely to hold the growth of the pulmonary segment. 

Distribution Channel Insights

The global peptide therapeutics market is segmented into Hospital pharmacies, retail pharmacies & online drug stores. The Hospital pharmacies segment is further subdivided into private and public Hospital pharmacies. The hospital pharmacies segment dominated the global market with the largest share of 39.95% in 2023. Peptide hormones are required to be prescribed by doctors; hospital pharmacies offer better input in prescribing decisions. 

Hospital pharmacies are also widely preferred as they carry patient data and medical history. The retail pharmacies segment is the fastest-growing global peptide therapeutics market. The online drugstore segment is predicted to be lucrative during the forecast period. 

Synthesis Technology Insights

Synthesis technology divides the global peptide therapeutics market into solid-phase peptide synthesis (SPPS), liquid-phase peptide synthesis (LPPS)& hybrid technology. The liquid-phase peptide synthesis segment dominated the market and generated more than 45.96% of the revenue share in 2023. 

LPPS technology is considered the most classical and pure approach to synthesis; this factor has boosted the demand for LPPS in recent years. Many researchers and developers have shifted to liquid-phase peptide synthesis from solid-phase. On the other hand, the solid phase peptide synthesis segment is showing significant growth in the market as it offers a faster yet effective synthesis process. 

Recent Developments

• In December 2022, a Japan-based biopharmaceutical company, PeptiDream Inc., announced a license agreement and strategic collaboration with Merck & Co, Inc. The strategic partnership aims to focus on discovering and developing novel peptide drugs. 
• In December 2022, PeptiDream Inc. announced that the company has entered into a licensing agreement and research collaboration with Eli Lilly & Company, a U.S.-based pharmaceutical company. The agreement focuses on the discovery and development of new peptide drug conjugates.
• In December 2022, the Research team from Technion and the University of Tokyo stated that their research study had identified unique peptides with potential anti-cancer properties. Such peptides with small chains of amino acids play a potential role in cancer treatment.
• In November 2022, Exelixis announced that it had entered into an exclusive collaboration with Cybrexa Therapeutics. The collaboration agreement aims to acquire CBX-12, a peptide drug conjugate. CBX-12 is designed to increase efficacy and reduce the toxicity of topoisomerase inhibitors.
• In November 2022, a clinical-stage biopharmaceutical company developing precision peptides, MBX Biosciences, announced the closing of $115 million series B financing. The funding aims to be utilized in the advanced development of endocrine disease programs.
• In October 2022, a private biotech company, Ariceum Therapeutics, and Ambio Pharm announced that they had entered a strategic manufacturing and supply partnership. This partnership aims to manufacture and supply peptide conjugates. Ariceum will use these new peptide conjugates for future clinical studies. 
• In July 2022, a biotech company, Peptilogics, announced that the U.S. Food & Drug Administration (FDA) had granted Fast Track Designation to the company for its lead drug candidate, PLG0206, for the treatment of periprosthetic joint infections.

Peptide Therapeutics Market Companies

• Eli Lilly & Company
• Amgen Inc.
• Pfizer, Inc.
• Ever Neuro Pharma GmbH
• Bausch Health
• Abbvie

Segments Covered in the Report:

By Application

• Gastrointestinal Disorder
• Metabolic Disorder
• Neurological Disorder
• Cancer 
• Others

By Type

• Generic
• Innovative 

By Route of Administration

• Oral
• Parenteral
• Pulmonary
• Mucosal
• Others 

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Drug Stores

By Synthesis Technology

• Solid Phase Peptide Synthesis (SPPS)
• Liquid Phase Peptide Synthesis (LPPS)
• Hybrid Technology

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East and Africa